Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide

FEBS Letters

Volumn 583, Issue 12, 2009, Pages 2067-2070

  Sonoyama, Takuhiro ^a   Tamura, Naohisa ^a   Miyashita, Kazutoshi ^a   Park, Kwijun ^a   Oyamada, Naofumi ^a   Taura, Daisuke ^a   Inuzuka, Megumi ^a   Fukunaga, Yasutomo ^a   Sone, Masakatsu ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain natriuretic peptide; Carbon tetrachloride; Guanylyl cyclase A; Hepatic stellate cell; Liver fibrosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBON TETRACHLORIDE; MESSENGER RNA; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CARBON TETRACHLORIDE; COLLAGEN TYPE I; HEPATIC STELLATE CELLS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NATRIURETIC PEPTIDE, BRAIN; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

MUS;

EID: 67349204034     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.05.025     Document Type: Article

References (16)

1. Tamura N., and Garbers D.L. Guanylyl cyclase receptors. In: Martini L. (Ed). Encyclopedia of Endocrine Diseases vol. 2 (2004), Academic Press, San Diego 415-421
2. Chalasani N., Gorski J.C., Asghar M.S., Asghar A., Foresman B., Hall S.D., and Crabb D.W. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37 (2003) 544-550
3. Wallace K., Burt A.D., and Wright M.C. Liver fibrosis. Biochem. J. 411 (2008) 1-18
4. Bradford B.U., Kono H., Isayama F., Kosyk O., Wheeler M.D., Akiyama T.E., Bleye L., Krausz K.W., Gonzalez F.J., Koop D.R., and Rusyn I. Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol-induced oxidative DNA damage in rodent liver. Hepatology 41 (2005) 336-344
5. Murakami S., Nagaya N., Itoh T., Fujii T., Iwase T., Hamada K., Kimura H., and Kangawa K. C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 287 (2004) L1172-7
6. Soeki T., Kishimoto I., Okumura H., Tokudome T., Horio T., Mori K., and Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 45 (2005) 608-616
7. Tamura N., Ogawa Y., Chusho H., Nakamura K., Nakao K., Suda M., Kasahara M., Hashimoto R., Katsuura G., Mukoyama M., Itoh H., Saito Y., Tanaka I., Otani H., and Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. USA 97 (2000) 4239-4244
8. Suganami T., Mukoyama M., Sugawara A., Mori K., Nagae T., Kasahara M., Yahata K., Makino H., Fujinaga Y., Ogawa Y., Tanaka I., and Nakao K. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J. Am. Soc. Nephrol. 12 (2001) 2652-2663
9. Ogawa Y., Itoh H., Tamura N., Suga S., Yoshimasa T., Uehira M., Matsuda S., Shiono S., Nishimoto H., and Nakao K. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J. Clin. Invest. 93 (1994) 1911-1921
10. Sone M., Itoh H., Yamahara K., Yamashita JK., Yurugi-Kobayashi T., Nonoguchi A., Suzuki Y., Chao T.H., Sawada N., Fukunaga Y., Miyashita K., Park K., Oyamada N., Sawada N., Taura D., Tamura N., Kondo Y., Nito S., Suemori H., Nakatsuji N., Nishikawa S., and Nakao K. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2127-2134
11. Tao J., Mallat A., Gallois C., Belmadani S., Méry P.F., Nhieu J.T., Pavoine C., and Lotersztajn S. Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells. J. Biol. Chem. 274 (1999) 23761-23769
12. Görbig M.N., Ginès P., Bataller R., Nicolás J.M., Garcia-Ramallo E., Tobías E., Titos E., Rey M.J., Clària J., Arroyo V., and Rodés J. Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology 30 (1999) 501-509
13. Bilzer M., Jaeschke H., Vollmar A.M., Paumgartner G., and Gerbes A.L. Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. Am. J. Physiol. 276 (1999) G1137-G1144
14. Ishigaki N., Yamamoto N., Jin H., Uchida K., Terai S., and Sakaida I. Continuous intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat. Biochem. Biophys. Res. Commun. 378 (2009) 354-359
15. Li Y., Kishimoto I., Saito Y., Harada M., Kuwahara K., Izumi T., Takahashi N., Kawakami R., Tanimoto K., Nakagawa Y., Nakanishi M., Adachi Y., Garbers D.L., Fukamizu A., and Nakao K. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 106 (2002) 1722-1728
16. Yamashita T., Tokutomi Y., Matsuba S., Ichijo H., Ogawa H., and Kim-Mitsuyama S. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 52 (2008) 573-580